Minerva (Cyproterone Acetate, Ethinylestradiol)

Cyproterone acetate and ethinylestradiol, the active ingredients in Minerva, are a combined oral contraceptive presented as an oral tablet for oral use. It prevents pregnancy and treats androgen‑dependent conditions such as acne and hirsutism in women of reproductive age.

GNH USA supplies Minerva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for export to EU and other markets. Timely logistics and post‑delivery support are also part of the service offering.

Minerva, a combined oral contraceptive, is indicated for several hormone‑related conditions. - Contraception: Prevents pregnancy by suppressing ovulation and altering cervical mucus and endometrial lining. - Acne: Reduces androgen‑driven skin lesions in women, improving facial and body acne. - Hirsutism: Decreases excessive hair growth associated with androgen excess. - Menstrual regulation: Helps establish predictable menstrual cycles and reduces menstrual‑related symptoms.

Minerva may cause a range of adverse reactions, which are grouped by frequency and severity.

Common Side Effects: - Nausea - Headache - Breast tenderness - Spotting between periods - Weight gain - Mood changes

Serious or Rare Side Effects: - Venous thromboembolism (deep‑vein thrombosis, pulmonary embolism) - Stroke or transient ischemic attack - Myocardial infarction - Severe liver dysfunction or jaundice - Allergic reactions including anaphylaxis - Hyperkalaemia, especially with potassium‑sparing diuretics

Before prescribing Minerva, clinicians should evaluate the following safety considerations. - Contraindications: Avoid use in women with a history of thromboembolic disorders, stroke, or myocardial infarction. - Smoking: Do not prescribe to women over 35 who smoke, due to increased cardiovascular risk. - Blood pressure: Monitor hypertensive patients closely, as oral contraceptives may elevate blood pressure. - Liver disease: Use with caution in active liver disease; severe hepatic impairment is a contraindication. - Pregnancy: Not for use during pregnancy (Category X) and must be discontinued if pregnancy occurs. - Store at ambient temperature: Keep below 25 °C in the original packaging, protected from moisture.

Minerva can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Rifampicin, carbamazepine, phenytoin, St. John’s wort: Enzyme inducers that markedly reduce contraceptive hormone levels. - Protease inhibitors (e.g., ritonavir): Increase hormone concentrations, raising the risk of thrombotic events. - Anticoagulants (warfarin): May diminish anticoagulant effect, requiring closer monitoring. - Antiepileptic drugs (phenobarbital, primidone): Decrease oral contraceptive efficacy.

Moderate Interactions (Monitor Closely): - Antifungals (ketoconazole) and macrolide antibiotics (erythromycin): Can raise plasma hormone levels, potentially increasing side‑effect risk. - Selective serotonin reuptake inhibitors (SSRIs): May exacerbate mood‑related side effects.